2005年毕业于东北林业大学，获理学学士学位;2011年毕业于北京大学，获理学博士学位。2011年8月至2016年7月先后在美国约翰霍普金斯大学和纪念斯隆凯特琳癌症研究所从事肿瘤生物学博士后研究;2016年8月受聘于中科院上海生化与细胞所，任研究员、研究组长、博士生导师。

　　我们以正常组织类器官、肿瘤类器官、小鼠模型和临床肿瘤标本为基础，运用分子细胞生物学的实验手段，研究成体干细胞和肿瘤祖细胞的分子调控网络以及肿瘤细胞抗药性的分子机理。目前的主要研究内容包括：

　　1) 研究成体干细胞和肿瘤祖细胞，寻找维持成体干细胞多能性的主要调控基因;

　　2) 组织器官的体外功能性构建;

　　3) 体外重建不同时期的肿瘤类器官模型，研究肿瘤细胞可塑性与肿瘤抗药性的分子机理;

　　4) 建立来源于中国癌症病人的类器官模型库，进行高通量药物筛选，发展新的抗癌药物。

1. Gao D. Personalized Cancer Organoid Models. Cell. (Invited perspectives for Cell’s 50th anniversary, in press)
2. Li F^#, Dai PF^#, Shi HL^#, Zhang YJ^#, He J, Gopalan A, Li D, Chen Y, Du YR, Xu GL, Yang WW*, Liang C*, Gao D*. LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer. Cell Res. Accepted
3. Guo WX^#, Zhang XY^#, Li L^#, Shao PF^#, Liang C^#, Zhang HJ, Wang SM, Peng YY, Liu K, Luo J, Ju Y, DeMarzo AM*, Yu C*, Chen LN*, Zhou B*, Gao D*. JAK/STAT signaling maintains an intermediate cell population during prostate basal cell fate determination. Nat Genet. Accepted
4. Huang PW^#, Gao WN^#, Fu CY^#, Wang M^#, Li YG^#, Chu BZ, He A, Li Y, Deng XM, Zhang YH, Kong Q, Yuan JX, Wang HB, Shi Y*, Gao D*, Qin RY*, Hunter T, Tian RJ*. Multidimensional proteomic landscape of intercellular signaling in the pancreatic tumor microenvironment. Nature. Accepted
5. Zhang XY^#, Wang J^#, Guo WX*, Zhang HJ, Zhou B, Chen Y, Gao D*. The cell fates of intermediate cell population in prostate development. Cell Insight. 2024 July; 100182.
6. Li F^#, Xing XD^#, Jin QQ^#, Wang XM^#, Dai PF^#, Han M^#, Shi HL, Zhang Z, Shao XL, Peng YY, Zhu YQ, Xu JY, Li D, Chen Y, Wu W, Wang Q, Yu C*, Chen LN*, Bai F*, Gao D*. Sex differences orchestrated by androgens at single-cell resolution. Nature. 2024 May;629(8010):193-200.
7. Zhu YJ^#, Tang SJ^#, Yuan QY^#, Fu J^#, He J^#, Liu Z, Zhao XF, Li YG, Zhao Y, Zhang YN, Zhang XY, Zhang YQ, Zhu YQ, Wang WW, Zheng B, Wu R, Wu T, Yang S, Qiu XY, Shen SY, Hu J, Chen LN*, Wang Y, Wang HY*, Gao D*, Chen L*. Integrated characterization of hepatobiliary tumor organoids provides potential landscape of pharmacogenomic interactions. Cell Rep Med. 2024 Jan 17:101375.
8. Li YG^#, Tang SJ^#, Shi XH^#, Lv JW^#, Wu XY^#, Zhang YH^#, Wang H, He J, Zhu YQ, Ju Y, Guo SW, Yang WW*, Yin HY*, Chen LN*, Gao D*, Jin G*. Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med. 2023 Sep 19;4(9):101162.
9. Li X^#, Li F^#, Ye F^#, Guo HT, Chen WT, Jin J, Wang YR, Dai PF, Shi HL, Tao HR, Dang WZ, Ding YL, Wang MC, Jiang HL, Chen KX, Zhang NX, Gao D*, Zhang YY*, Luo C*. Spermine is a natural suppressor of AR signaling in castration-resistant prostate cancer. Cell Rep. 2023 Jul 14;42(7):112798.
10. Gao D. Cell fate determination and lineage plasticity in prostate cancer. Asian J Androl. 2023 Mar;25(2):149-151.
11. Li L^#, Xu YL^#, Yan LL^#, Li X, Li F, Liu Z, Zhang CC, Yuan L*, Gao D*, Cheng X*, Chen LN*.  Dynamic network biomarker factors orchestrate cell-fate determination at tipping points during hESC differentiation. Innovation (Camb). 2022 Dec 20;4(1):100364.
12. He J^#, Cui HY^#, Shi XH, Jin QQ, Han XM, Han TT, Peng JY, Guo SW, Zhao Y, Zhou B, Chen LN, Chen L, Zeng YA, Wang HY*, Jin G*, Gao D*. Functional hepatobiliary organoids recapitulate liver development and reveal essential drivers of hepatobiliary cell fate determination. Life Medicine. 2022 Dec 07; lnac055.
13. Han M^#, Li F^#,*, Zhang YH^#, Dai PF, He J, Li YG, Zhu YQ, Zheng JK, Huang H, Bai F, Gao D*. FOXA2 drives lineage plasticity and Kit pathway activation in neuroendocrine prostate cancer. Cancer Cell. 2022 Nov 14;40(11):1306-1323.e8. Preview by Azad AA, Kostos L and Agarwal N, Cancer Cell, 2022 40:1266-1268; Research highlights by Nat Rev Urol, 2023 Jan;20(1):8; Cancer Discovery  2022 Nov 18:OF1.
14. Peng JY^#, Li F^#, Wang J, Wang CX, Jiang YA, He J, Yuan K, Bei JX, Wang V, Zhou B, Chen LN, Gao D*, Zhao Y*. Identification of a rare Gli1⁺ progenitor cell population contributing to liver regeneration during chronic injury. Cell Discovery. 2022 Nov 1;8(1):118.
15. Wang WW^#,  Ma LL^#, Zheng X^#, Yuan TG, Bao JX, Zhu YJ, Zhao XF, Zhao Y, Zong YL, Zhang YN, Shen SY, Qiu XY, Yang S, Wang HY*, Gao D*, Wang P*, Chen L*. Tumor specific circRNA-derived neoantigen peptide identification for hepatobiliary tumor. Engineering. 2022 DOI: 10.1016/j.eng.2022.06.008
16. Wang YQ, Zhang LP, Liu Y, Tang LL, He J, Sun XQ, Younis MH, Cui DX, Xiao HH, Gao D*, Kong XY*, Cai WB*, Song J*. Engineering CpG-ASO-Pt-loaded Macrophages (CAP@M) For Synergistic Chemo-/Gene-/Immuno-Therapy. Adv Healthc Mater. 2022 Aug;11(15):e2201178.
17. Wang WW^#, Yuan TG^#,  Ma LL^#, Zhu YJ^#, Bao JX, Zhao XF, Zhao Y, Zong YL, Zhang YN, Yang S, Qiu XY, Shen SY, Wu R, Wu T, Wang HY*, Gao D*, Wang P*, Chen L*. Hepatobiliary tumor organoids reveal HLA I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with ICIs. Adv Sci (Weinh). 2022 Aug;9(22):e2105810.
18. Shi XH^#, Li YG^#, Yuan QY^#, Tang SJ^#, Guo SW^#, Zhang YH, He J, Zhang XY, Han M, Liu Z, Zhu YQ, Gao SZ, Wang H, Xu XF, Zheng KL, Jing W, Chen LN*, Wang Y*, Jin G*, Gao D*. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Nat Commun. 2022 Apr 21;13(1):2169.
19. Gu YQ^#, Cao J^#, Zhang XY^#, Gao H^#, Wang YY^#, Wang J^#, He J^#, Jiang XY^#, Zhang JL, Shen GH, Yang J, Zheng XC, Hu GW, Zhu YF, Du SJ, Zhu YK, Zhang R, Xu JQ, Zhang CC, Lan F, Qu D, Xu GL, Zhao Y*, Gao D*, Xie YH*, Luo M*, Lu ZG*. Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. Cell Res. 2022 Jan;32(1):24-37.
20. Fu X^#, He Q^#, Tao Y^#, Wang DM^#, Wang W^#, Wang YL^#, Yu QC^#, Zhang F^#, Zhang XY^#, Chen YG*, Gao D*, Hu P*, Hui LJ*, Wang XQ*, Zeng YA*. Recent advances in tissue stem cells. Sci China Life Sci. 2021 Dec;64(12):1998-2029.
21. Zhao Y^#, Li ZX^#, Zhu YJ^#, Fu J^#, Zhao XF, Zhang YN, Wang S, Wu JM, Wang KT, Wu R, Sui CJ, Shen SY, Wu X, Wang HY*, Gao D*, Chen L*. Single cell transcriptome analysis uncovers intra-tumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor organoids. Adv Sci (Weinh). 2021 Jun;8(11):e2003897.
22. Li F^#, Han M^#, Dai PF^#, Xu W^#, He J^#, Tao XT^#, Wu Y^#, Tong XY, Xia XY, Guo WX, Zhou YJ, Li YG, Zhu YQ, Zhang XY, Liu Z, Aji R, Cai X, Li YT, Qu D, Chen Y, Jiang SB, Wang Q, Ji HB, Xie YH*, Sun YH*, Lu L*, Gao D*. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021 Feb 8;12(1):866.
23. Li F^#, Yuan QY^#, Di W^#, Xia XY^#, Liu Z, Mao NH, Li L, Li CF, He J, Li YG, Guo WX, Zhang XY, Zhu YQ, Aji R, Wang SQ, Chi P, Carver B, Wang Y*, Chen Y*, Gao D*. ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. J Clin Invest. 2020 Nov 2;130(11):5924-5941.
24. Guo WX^#, Li L^#, He J, Liu Z, Han M, Li F, Xia XY, Zhang XY, Zhu Y, Wei Y, Li YG, Aji R, Dai H, Wei H, Li CF, Chen Y*, Chen LN*, Gao D*. Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips.  Nat Genet. 2020 Sep;52(9):908-918.
25. He J, Zhang X, Xia XY, Han M, Li F, Li CF, Li YG, Gao D*. Organoid technology for tissue engineering. J Mol Cell Biol. 2020 Aug 1;12(8):569-579. (Invited review)
26. Tang J^#, Wang HX^#, Huang XZ^#, Li F^#, Zhu H, Li Y, He LJ, Zhang H, Pu WJ, Liu K, Zhao H, Bentzon JF, Yu Y, Ji Y, Nie Y, Zhang L*, Gao D*, Zhou B*. Sca1⁺ Vascular Stem Cells Contribute to Smooth Muscle for Artery Repair and Regeneration. Cell Stem Cell. 2020 Jan 2;26(1):81-96.
27. Xia XY, Li F, He J, Aji R, Gao D*. Organoid technology in cancer precision medicine. Cancer Lett. 2019 Aug 10;457:20-27. (Invited review)
28. Ding YF^#, Li N^#, Dong BJ^#, Guo WX, Wei H, Chen QL, Yuan HR, Han Y, Chang HW, Kan S, Wang XG, Pan Q, Wu P, Peng C, Qiu T, Li QT, Gao D*, Xue W*, Qin J*. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest. 2019 Feb 1;129(2):759-773.
29. Gao D^#, Vela I^#, Sboner A^#, Iaquinta PJ^#, Karthaus WL, Gopalan A, Wanjala JN, Dowling C, Undvall EA, Wongvipat J, Kossai M, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran Ll, Solomon SB, MacDonald TY, Beltran H, Mosquera J,  Eastham JA, Touijer KA, Scardino PT, Laudone VP, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Chi P, Clevers H, Carver B, Rubin MA, Scher HI, Sawyers CL*, Chen Y*. Generation of in vitro organoids cultures derived from patients with advanced prostate cancer. Cell. 2014 Sep; 159(1): 176-187.

合影